Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
3, 4 Methylenedioxymethamphetamine · 1 trial · 1 indication
The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a 20-item diagnostic interview administered by trained evaluators to assess PTSD in a participant. Based on DSM-5 diagnostic criteria, evaluators ask about the severity of four PTSD-related symptom clusters: re-experiencing, avoidance, negative alterations in cognition and mood, and alterations in arousal and reactivity. The evaluator rates responses on a 5-point Likert scale (0 = Absent to 4 = Extreme/Incapacitating). Total scores range from 0 to 80 with higher scores indicating greater severity.
| Arm | Type | Description |
|---|---|---|
| Dose A (exact dose not disclosed) | EXPERIMENTAL | Non-medicine sessions of PE + One Medicine Session with 3,4-methylenedioxymethamphetamine (MDMA) PE Non-medicine sessions: 12 sessions MDMA Medicine session: Dose: exact dose not disclosed |
| Dose B (exact dose not disclosed) | EXPERIMENTAL | Non-medicine sessions of PE + One Medicine Session with 3,4-methylenedioxymethamphetamine (MDMA) PE Non-medicine sessions: 12 sessions MDMA Medicine session: Dose: exact dose not disclosed |
| Name | Type | Description |
|---|---|---|
| 3,4 Methylenedioxymethamphetamine | DRUG | 1 MDMA session |
| Prolonged Exposure | BEHAVIORAL | 12 90-minute PE sessions; initial two sessions both occurring during the first treatment visit, third and fourth sessions occurring during the MDMA session, and the remaining sessions occurring daily or every other day |
Inclusion Criteria: 1. Be a veteran (age 18-64 years old) who meets criteria for PTSD on the CAPS-5 (severity ≥ 25). 2. Be fluent in speaking and reading English. 3. Are willing to commit to medication dosing, therapy sessions, follow-up sessions, completing evaluation instruments, and all necessar...
3,4 Methylenedioxymethamphetamine, also known as MDMA, is being investigated for the treatment of Post-Traumatic Stress Disorder (PTSD). It is a small molecule being developed by National Healthcare Corp. (NHC) and is currently in Phase 3 clinical trials.
3,4 Methylenedioxymethamphetamine is being developed by National Healthcare Corp., which trades under the ticker NHC. The company is conducting a Phase 3 clinical trial for the drug in the treatment of Post-Traumatic Stress Disorder.
3,4 Methylenedioxymethamphetamine is in Phase 3 clinical development for Post-Traumatic Stress Disorder. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 3 trial is currently recruiting participants.
3,4 Methylenedioxymethamphetamine is being studied in a Phase 3 clinical trial with the identifier NCT06117306, titled 'MDMA-assisted Massed Prolonged Exposure for PTSD'. This randomized, double-blind, controlled trial is recruiting 20 participants in the United States.
Yes, 3,4 Methylenedioxymethamphetamine is also known as MDMA. It is being studied in a Phase 3 clinical trial for Post-Traumatic Stress Disorder, with the trial NCT06117306 evaluating MDMA-assisted therapy.